Outcomes with tacrolimus-based immunosuppression after kidney transplantation from standard- and extended-criteria donors - a post hoc analysis of the prospective OSAKA study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F20%3A00079716" target="_blank" >RIV/00023001:_____/20:00079716 - isvavai.cz</a>
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282531/pdf/anntransplant-25-e920041.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282531/pdf/anntransplant-25-e920041.pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.12659/AOT.920041" target="_blank" >10.12659/AOT.920041</a>
Alternative languages
Result language
angličtina
Original language name
Outcomes with tacrolimus-based immunosuppression after kidney transplantation from standard- and extended-criteria donors - a post hoc analysis of the prospective OSAKA study
Original language description
Background: This post hoc analysis of data from the prospective OSAKA study evaluated the efficacy and safety of prolonged- and immediate-release tacrolimus in patients who received kidneys from extended-criteria (ECD) and standard-criteria (SCD) donors. Material/Methods: Within the ECD and SCD groups, patients were randomized to one of 4 tacrolimus-based regimens (initial dose): Arm 1, immediate-release tacrolimus (0.2 mg/kg/day); Arm 2, prolonged-release tacrolimus (0.2 mg/kg/day); Arm 3, prolonged-release tacrolimus (0.3 mg/kg/day); Arm 4, prolonged-release tacrolimus (0.2 mg/kg/day) plus basiliximab. All patients received mycophenolate mofetil and bolus corticosteroids; Arms 1-3 also received tapered corticosteroids. ECDs met the definition: living/deceased donors aged >= 60 years, or 50-60 years with >= 1 other risk factor, and donation after circulatory death. Primary composite endpoint: graft loss, biopsy-confirmed acute rejection or renal dysfunction by Day 168. Outcomes were compared across treatment arms with the chi-squared or Fisher's exact test. Results: A total of 1198 patients were included in the analysis (ECD: n=620 [51.8%], SCD: n=578 [48.2%]). Patients with kidneys from ECDs were older versus SCDs (mean age, 55.7 vs. 44.5 years, p<0.0001). A higher proportion of patients with kidneys from ECDs versus SCDs met the primary composite endpoint (56.8% vs. 32.4%, p<0.0001). However, no statistically significant differences in clinical outcomes or the incidence of treatment-emergent adverse events were seen between treatment arms within each donor group. Conclusions: Worse outcomes were experienced in patients who received kidneys from ECDs versus SCDs. Prolonged-release tacrolimus provided similar graft survival to the immediate-release formulation, with a manageable tolerability profile.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30213 - Transplantation
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Annals of transplantation
ISSN
1425-9524
e-ISSN
—
Volume of the periodical
25
Issue of the periodical within the volume
May
Country of publishing house
PL - POLAND
Number of pages
13
Pages from-to
"art. no. e920041"
UT code for WoS article
000537761900001
EID of the result in the Scopus database
2-s2.0-85085677308